Ligand Pharmaceuticals Incorporated (LGND)
Nasdaq · Healthcare · Biotechnology
$306.77+1.26%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $6.1B
- P/E (trailing)
- 32.3
- Forward P/E
- 25.7
- 52-week range
- $175.89 – $326.63
- 52-week change
- +65.91%
- EPS (trailing)
- $9.49
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $268M (+60.41%)
- Net income
- $124M
- Operating margin
- 15.3%
- Diluted EPS
- $6.13
- Free cash flow
- $48.9M
From the company’s annual report on SEC EDGAR.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.
Headquarters: Jupiter, United States · 47 employees · ligand.com